I would describe myself as a barbell investor focused on two ends of the risk spectrum: relatively safe, income-generating investments on one side, and high-risk, high upside opportunities—primarily binary healthcare and biotech bets—on the other. Professionally, I work as an R&D researcher in the pharmaceutical industry. Combined with my background in economics and self-training in finance, this provides me with unique perspective when evaluating biotech companies. My research spans multiple dimensions of the sector, including platform technologies, IP and freedom-to-operate considerations, mechanistic feasibility, competitive landscapes, binary clinical trial readouts and corporate financials. As an individual investor, I place significant emphasis on valuation, risk management and capital allocation. On the income-investing side of the portfolio, I actively follow dividend paying stock picks, including preferred shares, REITs, BDCs and option-based income ETFs. The objective is to build a durable stream of cash flow that can support moonshot bets on the other side of the barbell. Through my writing on Seeking Alpha, I aim to share independent, research-driven investment ideas from both ends of this barbell approach. My goal is to combine scientific insight, fundamental analysis and risk management to encourage disciplined trading and develop well-grounded investment thesis.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of AB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.